Immunovant Balance Sheet Analysis

Assets, liabilities, and stockholders equity in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Immunovant, Inc. (IMVT) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Current Assets
Cash and Cash Equivalents0.710.640.380.490.400.10
Cash & Short-Term Investments0.710.640.380.490.400.10
Accounts Receivable0.000.010.000.010.000.00
Inventory0.000.000.000.000.000.00
Other Current Assets0.050.020.030.010.010.00
Total Current Assets0.770.670.400.510.410.11
Non-Current Assets
Property, Plant & Equipment (Net)0.000.000.000.000.000.00
Other Non-Current Assets0.010.000.000.000.000.00
Total Non-Current Assets0.010.000.000.000.000.00
Total Assets0.780.670.410.520.410.11
Current Liabilities
Accounts Payable0.020.010.000.020.000.01
Short-Term Debt0.000.000.000.000.000.00
Accrued Liabilities0.050.030.040.020.020.00
Other Current Liabilities0.050.000.000.000.000.00
Total Current Liabilities0.070.050.040.040.020.02
Non-Current Liabilities
Long-Term Debt0.000.000.000.000.000.00
Other Non-Current Liabilities0.000.000.000.000.000.00
Total Non-Current Liabilities0.000.000.000.000.000.00
Total Liabilities0.070.050.040.050.020.02
Stockholders' Equity
Common Stock0.000.000.000.000.000.00
Retained Earnings-1.24-0.83-0.57-0.36-0.20-0.09
Accumulated Other Comprehensive Income0.000.000.000.000.000.00
Additional Paid-in Capital1.951.440.930.820.590.19
Shares Outstanding0.170.150.130.120.000.00
Total Stockholders' Equity0.710.620.360.470.390.09
Total Liabilities & Equity0.780.670.410.520.410.11